Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder(OAB): a Double-Blind Phase Followed by an Open-Label Extension Phase

NCT00220389 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00220389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00220389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder(OAB): a Double-Blind Phase Followed by an Open-Label Extension Phase
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2003
Completion date
June 30, 2007
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder